Determination of Antibody-Drug Conjugate Released Payload Species Using Directed in Vitro Assays and Mass Spectrometric Interrogation

Bioconjugate Chemistry

Volumn 27, Issue 7, 2016, Pages 1645-1654

  Bessire, Andrew J ^a   Ballard, T Eric ^a   Charati, Manoj ^b   Cohen, Justin ^a   Green, Michael ^a   Lam, My Hanh ^b   Loganzo, Frank ^b   Nolting, Birte ^b   Pierce, Betsy ^a   Puthenveetil, Sujiet ^a   Roberts, Lee ^a   Schildknegt, Klaas ^a   Subramanyam, Chakrapani ^a  

^a PFIZER INC   (United States)

^b Pfizer Worldwide Research and Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES; ASSAYS; CONTROLLED DRUG DELIVERY; DRUG PRODUCTS; ENZYMES; MASS SPECTROMETRY;

ACTIVE AREA; ACTIVE DRUGS; ANTIBODY-DRUG CONJUGATES; CONDITION; IN-VITRO; IN-VITRO ASSAYS; INFECTIOUS DISEASE; LYSOSOMAL ENZYMES; PERFORMANCE; VITRO METHOD;

TARGETED DRUG DELIVERY;

ANTIBODY CONJUGATE; ANTIBODY DRUG CONJUGATE; AZITHROMYCIN; CATHEPSIN B; CLOPIDOGREL; DILTIAZEM; ESTERASE; LYSOSOME ENZYME; UNCLASSIFIED DRUG; DRUG CARRIER;

ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MASS SPECTROMETRY; RADIOASSAY; ANIMAL; CHEMISTRY; CYTOLOGY; DRUG RELEASE; ENZYMOLOGY; LIVER; LYSOSOME; METABOLISM; MOUSE; RAT; TUMOR CELL LINE;

ANIMALS; CATHEPSIN B; CELL LINE, TUMOR; DRUG CARRIERS; DRUG LIBERATION; HUMANS; IMMUNOCONJUGATES; LIVER; LYSOSOMES; MASS SPECTROMETRY; MICE; RATS;

EID: 84979503092     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/acs.bioconjchem.6b00192     Document Type: Article

References (41)

1. Gordon, M. R., Canakci, M., Li, L., Zhuang, J., Osborne, B., and Thayumanavan, S. (2015) Field Guide to Challenges and Opportunities in Antibody-Drug Conjugates for Chemists Bioconjugate Chem. 26, 2198-2215 10.1021/acs.bioconjchem.5b00399
2. Kim, E. G. and Kim, K. M. (2015) Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics Biomol. Ther. 23, 493-509 10.4062/biomolther.2015.116
3. Lehar, S. M., Pillow, T., Xu, M., Staben, L., Kajihara, K. K., Vandlen, R., DePalatis, L., Raab, H., Hazenbos, W. L., and Morisaki, J. H. et al. 2015, Novel antibody-antibiotic conjugate eliminates intracellular S. aureus Nature 527, 323-328 10.1038/nature16057
4. Aboud-Pirak, E., Sergent, T., Otte-Slachmuylder, C., Abarca, J., Trouet, A., and Schneider, Y. J. (1988) Binding and endocytosis of a monoclonal antibody to a high molecular weight human milk fat globule membrane-associated antigen by cultured MCF-7 breast carcinoma cells Cancer Res. 48, 3188-3196
5. Sutherland, M. S., Sanderson, R. J., Gordon, K. A., Andreyka, J., Cerveny, C. G., Yu, C., Lewis, T. S., Meyer, D. L., Zabinski, R. F., and Doronina, S. O. et al. 2006, Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates J. Biol. Chem. 281, 10540-10547 10.1074/jbc.M510026200
6. Omelyanenko, V., Gentry, C., Kopeckova, P., and Kopecek, J. (1998) HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. II. Processing in epithelial ovarian carcinoma cells in vitro Int. J. Cancer 75, 600-608 10.1002/(SICI)1097-0215(19980209)75:4<600::AID-IJC18>3.0.CO;2-C
7. Hamann, P. R., Hinman, L. M., Beyer, C. F., Lindh, D., Upeslacis, J., Flowers, D. A., and Bernstein, I. (2002) An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker Bioconjugate Chem. 13, 40-46 10.1021/bc0100206
8. Doronina, S. O., Toki, B. E., Torgov, M. Y., Mendelsohn, B. A., Cerveny, C. G., Chace, D. F., DeBlanc, R. L., Gearing, R. P., Bovee, T. D., and Siegall, C. B. et al. 2003, Development of potent monoclonal antibody auristatin conjugates for cancer therapy Nat. Biotechnol. 21, 778-784 10.1038/nbt832
9. Willner, D., Trail, P. A., Hofstead, S. J., King, H. D., Lasch, S. J., Braslawsky, G. R., Greenfield, R. S., Kaneko, T., and Firestone, R. A. (1993) 6-Maleimidocaproyl)hydrazone of doxorubicin - a new derivative for the preparation of immunoconjugates of doxorubicin Bioconjugate Chem. 4, 521-527 10.1021/bc00024a015
10. Braslawsky, G. R., Kadow, K., Knipe, J., McGoff, K., Edson, M., Kaneko, T., and Greenfield, R. S. (1991) Adriamycin(hydrazone)-antibody conjugates require internalization and intracellular acid hydrolysis for antitumor activity Cancer Immunol. Immunother. 33, 367-374 10.1007/BF01741596
11. Dubowchik, G. M., Firestone, R. A., Padilla, L., Willner, D., Hofstead, S. J., Mosure, K., Knipe, J. O., Lasch, S. J., and Trail, P. A. (2002) Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity Bioconjugate Chem. 13, 855-869 10.1021/bc025536j
12. Doronina, S. O., Mendelsohn, B. A., Bovee, T. D., Cerveny, C. G., Alley, S. C., Meyer, D. L., Oflazoglu, E., Toki, B. E., Sanderson, R. J., and Zabinski, R. F. et al. 2006, Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity Bioconjugate Chem. 17, 114-124 10.1021/bc0502917
13. Erickson, H. K., Park, P. U., Widdison, W. C., Kovtun, Y. V., Garrett, L. M., Hoffman, K., Lutz, R. J., Goldmacher, V. S., and Blattler, W. A. (2006) Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing Cancer Res. 66, 4426-4433
14. Dubowchik, G. M. and Firestone, R. A. (1998) Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin Bioorg. Med. Chem. Lett. 8, 3341-3346 10.1016/S0960-894X(98)00609-X
15. Dubowchik, G. M., Mosure, K., Knipe, J. O., and Firestone, R. A. (1998) Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), mitomycin C and doxorubicin Bioorg. Med. Chem. Lett. 8, 3347-3352 10.1016/S0960-894X(98)00610-6
16. Barrett, A. J. and Kirschke, H. (1981) Cathepsin B, Cathepsin H, and cathepsin L Methods Enzymol. 80, 535-561 10.1016/S0076-6879(81)80043-2
17. Vaishampayan, U., Glode, M., Du, W., Kraft, A., Hudes, G., Wright, J., and Hussain, M. (2000) Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma Clin. Cancer Res. 6, 4205-4208
18. Madden, T., Tran, H. T., Beck, D., Huie, R., Newman, R. A., Pusztai, L., Wright, J. J., and Abbruzzese, J. L. (2000) Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors Clin. Cancer Res. 6, 1293-1301
19. Strop, P., Liu, S. H., Dorywalska, M., Delaria, K., Dushin, R. G., Tran, T. T., Ho, W. H., Farias, S., Casas, M. G., and Abdiche, Y. et al. 2013, Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates Chem. Biol. 20, 161-167 10.1016/j.chembiol.2013.01.010
20. Murata, M., Miyashita, S., Yokoo, C., Tamai, M., Hanada, K., Hatayama, K., Towatari, T., Nikawa, T., and Katunuma, N. (1991) Novel epoxysuccinyl peptides. Selective inhibitors of cathepsin B, in vitro FEBS Lett. 280, 307-310 10.1016/0014-5793(91)80318-W
21. Bohley, P. and Seglen, P. O. (1992) Proteases and proteolysis in the lysosome Experientia 48, 151-157 10.1007/BF01923508
22. Sanderson, R. J., Nicholas, N. D., Baker Lee, C., Hengel, S. M., Lyon, R. P., Benjamin, D. R., and Alley, S. C. (2016) Antibody-conjugated drug assay for protease-cleavable antibody-drug conjugates Bioanalysis 8, 55-63 10.4155/bio.15.230
23. Takio, K., Towatari, T., Katunuma, N., Teller, D. C., and Titani, K. (1983) Homology of amino acid sequences of rat liver cathepsins B and H with that of papain Proc. Natl. Acad. Sci. U. S. A. 80, 3666-3670 10.1073/pnas.80.12.3666
24. Turk, B., Turk, D., and Turk, V. (2000) Lysosomal cysteine proteases: more than scavengers Biochim. Biophys. Acta, Protein Struct. Mol. Enzymol. 1477, 98-111 10.1016/S0167-4838(99)00263-0
25. Portnoy, D. A., Erickson, A. H., Kochan, J., Ravetch, J. V., and Unkeless, J. C. (1986) Cloning and characterization of a mouse cysteine proteinase J. Biol. Chem. 261, 14697-14703
26. Alley, S. C., Zhang, X., Okeley, N. M., Anderson, M., Law, C. L., Senter, P. D., and Benjamin, D. R. (2009) The pharmacologic basis for antibody-auristatin conjugate activity J. Pharmacol. Exp. Ther. 330, 932-938 10.1124/jpet.109.155549
27. Narciso, J. E., Uy, I. D., Cabang, A. B., Chavez, J. F., Pablo, J. L., Padilla-Concepcion, G. P., and Padlan, E. A. (2011) Analysis of the antibody structure based on high-resolution crystallographic studies New Biotechnol. 28, 435-447 10.1016/j.nbt.2011.03.012
28. Plant, N. (2004) Strategies for using in vitro screens in drug metabolism Drug Discovery Today 9, 328-336 10.1016/S1359-6446(03)03019-8
29. Mueller, G. C. and Miller, J. A. (1949) The reductive cleavage of 4-dimethylaminoazobenzene by rat liver; the intracellular distribution of the enzyme system and its requirement for triphosphopyridine nucleotide J. Biol. Chem. 180, 1125-1136
30. Omura, T. (1999) Forty years of cytochrome P450 Biochem. Biophys. Res. Commun. 266, 690-698 10.1006/bbrc.1999.1887
31. Gemzik, B., Halvorson, M. R., and Parkinson, A. (1990) Pronounced and differential effects of ionic strength and pH on testosterone oxidation by membrane-bound and purified forms of rat liver microsomal cytochrome P-450 J. Steroid Biochem. 35, 429-440 10.1016/0022-4731(90)90251-M
32. Mera, Y., Odani, N., Kawai, T., Hata, T., Suzuki, M., Hagiwara, A., Katsushima, T., and Kakutani, M. (2011) Pharmacological characterization of diethyl-2-({3-dimethylcarbamoyl-4-[(4′-trifluoromethylbiphenyl-2-carbonyl)amino]p henyl}acetyloxymethyl)-2-phenylmalonate (JTT-130), an intestine-specific inhibitor of microsomal triglyceride transfer protein J. Pharmacol. Exp. Ther. 336, 321-327 10.1124/jpet.110.173807
33. Ryder, T., Walker, G. S., Goosen, T. C., Ruggeri, R. B., Conn, E. L., Rocke, B. N., Lapham, K., Steppan, C. M., Hepworth, D., and Kalgutkar, A. S. (2012) Insights into the novel hydrolytic mechanism of a diethyl 2-phenyl-2-(2-arylacetoxy)methyl malonate ester-based microsomal triglyceride transfer protein (MTP) inhibitor Chem. Res. Toxicol. 25, 2138-2152 10.1021/tx300243v
34. Ballard, T. E., Dahal, U. P., Bessire, A. J., Schneider, R. P., Geoghegan, K. F., and Vaz, A. D. (2015) A tag-free collisionally induced fragmentation approach to detect drug-adducted proteins by mass spectrometry Rapid Commun. Mass Spectrom. 29, 2175-2183 10.1002/rcm.7375
35. Brezski, R. J., Vafa, O., Petrone, D., Tam, S. H., Powers, G., Ryan, M. H., Luongo, J. L., Oberholtzer, A., Knight, D. M., and Jordan, R. E. (2009) Tumor-associated and microbial proteases compromise host IgG effector functions by a single cleavage proximal to the hinge Proc. Natl. Acad. Sci. U. S. A. 106, 17864-17869 10.1073/pnas.0904174106
36. Fan, X., Brezski, R. J., Fa, M., Deng, H., Oberholtzer, A., Gonzalez, A., Dubinsky, W. P., Strohl, W. R., Jordan, R. E., and Zhang, N. et al. 2012, A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacy Breast Cancer Res. 14, R116 10.1186/bcr3240
37. Schneider, Y. J., de Duve, C., and Trouet, A. (1981) Fate of plasma membrane during endocytosis. III. Evidence for incomplete breakdown of immunoglobulin in lysosomes of cultured fibroblasts J. Cell Biol. 88, 380-387 10.1083/jcb.88.2.380
38. Kraynov, E., Kamath, A. V., Walles, M., Tarcsa, E., Deslandes, A., Iyer, R. A., Datta-Mannan, A., Sriraman, P., Bairlein, M., and Yang, J. J. et al. 2016, Current Approaches for ADME Characterization of Antibody-Drug Conjugates: An Industry White Paper Drug Metab. Dispos. 44, 617 10.1124/dmd.115.068049
39. Rock, B. M., Tometsko, M. E., Patel, S. K., Hamblett, K. J., Fanslow, W. C., and Rock, D. A. (2015) Intracellular Catabolism of an Antibody Drug Conjugate with a Noncleavable Linker Drug Metab. Dispos. 43, 1341-1344 10.1124/dmd.115.064253
40. Berk, S. C., et al., (2007). Spirocyclic compounds. US Patent No. 7,834,026.
41. Subramanyam, C., et al., (2014). Spliceostatin analogs and methods for their preparation. US Patent No. 9,169,264.